NASDAQ:TARA

Protara Therapeutics (TARA) Stock Price, News & Analysis

Protara Therapeutics logo
$2.31 -0.08 (-3.15%)
As of 02:21 PM Eastern
This is a fair market value price provided by Massive. Learn more.

About Protara Therapeutics Stock (NASDAQ:TARA)

Advanced

Key Stats

Today's Range
$2.24
▼
$2.43
50-Day Range
$2.13
▼
$3.91
52-Week Range
$2.09
▼
$7.82
Volume
432,112 shs
Average Volume
883,235 shs
Market Capitalization
$141.92 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$26.25
Consensus Rating
Moderate Buy

Company Overview

Protara Therapeutics is a clinical-stage biotechnology company developing treatments for cancer and rare diseases. Its programs are investigational and are not approved for general use.

The company’s lead program, TARA-002, is a cell-based immunotherapy being studied for non-muscle invasive bladder cancer and lymphatic malformations. Protara is also developing intravenous choline chloride for people with intestinal failure-associated liver disease.

Protara was formed in 2019 through a merger involving ArTara Therapeutics. Its research and development activities focus on advancing these programs through clinical testing.

AI Generated. May Contain Errors.

Protara Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
57th Percentile Overall Score

TARA MarketRank™: 
2.851837113675 of 5 stars

Protara Therapeutics scored higher than 57% of companies evaluated by MarketBeat, and ranked 234th out of 877 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Protara Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on no strong buy ratings, 7 buy ratings, no hold ratings, and 1 sell rating.

  • Upside Potential

    Protara Therapeutics has a consensus price target of $26.25, representing about 1,029.0% upside from its current price of $2.33.

  • Amount of Analyst Coverage

    Protara Therapeutics has only been the subject of 2 research reports in the past 90 days.

  • Read more about Protara Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Protara Therapeutics are expected to decrease in the coming year, from ($1.37) to ($1.65) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Protara Therapeutics is -1.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Protara Therapeutics is -1.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Protara Therapeutics has a P/B Ratio of 1.02. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    5.93% of the float of Protara Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Protara Therapeutics has a short interest ratio ("days to cover") of 2.87, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Protara Therapeutics has recently decreased by 46.89%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Protara Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Protara Therapeutics does not have a long track record of dividend growth.

  • News Sentiment

    Protara Therapeutics has a news sentiment score of 0.95. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.58 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 16 news articles for Protara Therapeutics this week, compared to 3 articles on an average week.
  • Search Interest

    Only 1 people have searched for TARA on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.
  • MarketBeat Follows

    Only 1 people have added Protara Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Protara Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    7.60% of the stock of Protara Therapeutics is held by insiders.

  • Percentage Held by Institutions

    38.13% of the stock of Protara Therapeutics is held by institutions.

  • Read more about Protara Therapeutics' insider trading history.
Receive TARA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Protara Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

TARA Stock News Headlines

HC Wainwright Has Bullish Outlook for TARA FY2026 Earnings
Your Copy is on Hold (Claim it now)
James Altucher, who called NVIDIA in 2008 and SpaceX years before a single share traded, has a new report on Elon Musk's next big industry play. He estimates it could create 1.8 million new millionaires in the coming years, and shows how to position in the company at its center for under $60. Inside: the company's name and ticker, plus an FCC filing James believes reveals Elon's plan to take over a $25 trillion industry. He also flags December 8 as a key date.tc pixel
TARA Stock Earnings Estimates Decreased by HC Wainwright
See More Headlines

TARA Stock Analysis - Frequently Asked Questions

Protara Therapeutics' stock was trading at $5.33 at the beginning of 2026. Since then, TARA shares have decreased by 56.4% and is now trading at $2.3250.

Protara Therapeutics, Inc. (NASDAQ:TARA) announced its earnings results on Friday, November, 6th. The company reported ($0.35) earnings per share for the quarter, topping analysts' consensus estimates of ($0.37) by $0.02.

Protara Therapeutics (TARA) raised $79 million in an IPO on Wednesday, October 22nd 2014. The company issued 6,110,000 shares at $12.00-$14.00 per share.

Top institutional investors of Protara Therapeutics include Baker BROS. Advisors LP (2.99%), Marshall Wace LLP (2.51%), Integral Health Asset Management LLC (2.03%) and State Street Corp (1.70%). Insiders that own company stock include Jacqueline Zummo, Jacqueline Zummo and Opaleye Management Inc.
View institutional ownership trends
.

Shares of TARA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Protara Therapeutics investors own include Iovance Biotherapeutics (IOVA), Viking Therapeutics (VKTX), Alibaba Group (BABA), Pfizer (PFE), Definium Therapeutics (DFTX), Intel (INTC) and FuelCell Energy (FCEL).

Company Calendar

Last Earnings
11/06/2026
Today
11/17/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biotechnology
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:TARA
Previous Symbol
NASDAQ:PRTO
CIK
1359931
Employees
51
Year Founded
2017

Price Target and Rating

High Price Target
$28.00
Low Price Target
$24.00
Potential Upside/Downside
+1,038.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.75
Research Coverage
8 Analysts

Profitability

EPS (Trailing Twelve Months)
($1.39)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$57.44 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-46.15%
Return on Assets
-42.75%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
9.01
Quick Ratio
10.97

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$2.29 per share
Price / Book
1.01

Miscellaneous

Outstanding Shares
61,570,000
Free Float
56,891,000
Market Cap
$141.92 million
Optionable
Optionable
Beta
1.54

Social Links

Don't Wait for the OpenAI IPO Cover

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

This page (NASDAQ:TARA) was last updated on 11/17/2026 by MarketBeat.com Staff.
From Our Partners